BiotechTube
CritiTech

CritiTech

Lawrence, United States· Est.
crititech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Founded in 1997 and headquartered in Lawrence, Kansas, CritiTech is a private, revenue-generating CDMO/CRO that provides end-to-end drug development services. The company differentiates itself through its proprietary Purcision™ supercritical precipitation (SCP) technology and deep expertise in spray drying, aimed at solving complex formulation challenges for poorly soluble compounds. With a client base that includes top pharmaceutical companies and a successful track record of advancing drugs into Phase II trials, CritiTech positions itself as a collaborative partner invested in its clients' success.

Oncology

Technology Platform

Proprietary Purcision™ Supercritical Precipitation (SCP) technology for particle engineering and solubility/bioavailability enhancement, complemented by robust Spray Drying capabilities and expertise in inhaled drug development.

Funding History

2
Total raised:$2.5M
Debt$2M
Grant$500K

Opportunities

The growing trend of pharmaceutical outsourcing and the high prevalence of poorly soluble drug candidates create a large, sustained market for CritiTech's specialized particle engineering services.
Expansion into fill-finish and dedicated cytotoxic manufacturing capacity allows the company to capture more value from client programs and serve the high-demand oncology segment more comprehensively.

Risk Factors

Revenue is dependent on the success and timelines of client drug programs, creating pipeline concentration risk.
The company faces competition from other CDMOs with alternative solubility enhancement technologies.
Operational execution risks in GMP manufacturing, especially for cytotoxic compounds, could impact reputation and financial performance.

Competitive Landscape

CritiTech competes in a crowded CDMO market against large, full-service players (e.g., Lonza, Catalent) and smaller, niche technology providers. Its differentiation lies in the proprietary Purcision™ SCP platform and deep expertise in particle engineering for solubility challenges, particularly in oncology. Success hinges on demonstrating superior technical outcomes and a true partnership approach compared to more transactional competitors.

More companies in Small Molecule Drugs →More companies in United States →